ClinicalTrials.gg
CompletedNCT00627523EGNUpdated Nov 4, 2014Results posted

Genotropin Treatment In Very Young Children Born Small For Gestational Age

A Phase 3 interventional study of Genotropin (PN-180,307) Somatropin and Control-no treatment in Infant, Small for Gestational Age, sponsored by Pfizer. Completed at 17 sites in 9 countries. Open to participants aged 19 Months to 29 Months. Per ClinicalTrials.gov, last updated 2014-11-04.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
19 Months to 29 Months
Sex
All
01

Study summary

To demonstrate the effect on height and psychomotor development of Growth Hormone treatment in very young children starting at an age of 2 years.

02

Conditions studied

  • Infant, Small for Gestational Age
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Months to 29 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Caucasian male or female subjects aged between 19-29 months at Screening Visit 1.

Born SGA (birth length and/or weight \<-2 SD for gestational age, using country-specific standards).

Height below -2.5 SD at screening (19-29 months of age). At least one measurement of length between 12 and 18 months of age. Normal karyotype in girls to exclude Turners syndrome.

Exclusion criteria

Exclusion Criteria:

Severe Intra-Uterine Growth Retardation (IUGR) (birth length below - 4 SD for gestational age), if associated with dysmorphic features.

Severe prematurity (Gestational Age (GA) \<32 weeks of gestation). Ongoing catch-up growth (defined as growth velocity SDS at inclusion >0) based on at least 4 months measurement interval).

Severe familial short stature defined as: Father's height below 155 cm or mother's height below 145 cm.

Defined neurological defects and/or severe neurodevelopmental delay.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Active

    The active treatment arm

    Drug: Genotropin (PN-180,307) Somatropin

  • Experimental
    Control

    Control

    Drug: Control-no treatment

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Height Standard Deviation Score (SDS) at Month 24.

    Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.

    Time frame: Baseline and Month 24

Secondary outcomes

  1. Change From Baseline in Growth Velocity SDS at Month 24.

    The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.

    Time frame: Baseline and Month 24

  2. Change From Baseline in Height SDS at Month 12.

    Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.

    Time frame: Baseline and Month 12

  3. Change From Baseline in Growth Velocity SDS at Month 12.

    The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.

    Time frame: Baseline and Month 12

  4. Change From Baseline in Mental Development Using the Mental Development Index (MDI) of Bayley Scale at Month 12.

    The Bayley Scale of Infant Development (BSID-II) measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the mental raw score which was used to calculate the MDI score. Possible MDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.

    Time frame: Baseline and Month 12

  5. Change From Baseline in Psychomotor Development Using the Psychomotor Development Index (PDI) of Bayley Scale at Month 12.

    BSID-II measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the psychomotor raw score which was used to calculate the PDI score. Possible PDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.

    Time frame: Baseline and Month 12

  6. Head Circumference SDS at Months 3, 6, 12, 18 and 24.

    Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/ Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.

    Time frame: Months 3, 6, 12, 18 and 24

  7. Change From Baseline in Head Circumference SDS at Months 3, 6, 12, 18 and 24.

    Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.

    Time frame: Baseline, Months 3, 6, 12, 18 and 24.

  8. Change From Baseline in Body Weight at Months 3, 6, 12, 18, and 24.

    Body weight was measured at all the relevant visits. The change from Baseline in body weight was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.

    Time frame: Baseline, Months 3, 6, 12, 18, and 24

  9. Change From Baseline in Body Mass Index (BMI) at Months 3, 6, 12, 18, and 24.

    Body mass index was calculated for all visits by means of the following formula: BMI (kg/m2) = Weight (kg)/(Height\[m\])2. The change from Baseline BMI was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.

    Time frame: Baseline, Months 3, 6, 12, 18, and 24

07

Results

Posted Sep 18, 2014

Participant flow

This randomized controlled trial enrolled small for gestational age (SGA) children at 16 centers in 8 countries. In total, 52 participants were screened for the study, of these, 9 participants were considered screen failures. The remaining 43 participants were randomized to receive either study drug (Genotropin®) or were not treated (Control).

Participant flow — Overall Study
MilestoneGenotropin®Control
Started2122
Completed1920
Not completed22
Withdrew: Lack of efficacy10
Withdrew: Withdrawal by subject02
Withdrew: Other10

Outcome measures

PrimaryChange From Baseline in Height Standard Deviation Score (SDS) at Month 24.

Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · SDS
Change From Baseline in Height Standard Deviation Score (SDS) at Month 24.
SDSGenotropin®Control
Change From Baseline in Height Standard Deviation Score (SDS) at Month 24.1.63 ± 0.130.43 ± 0.13
Statistical analysis
  • Genotropin® vs Control · ANCOVA · p = <0.001 (ANCOVA model, fitting treatment as a factor, and the baseline parameter value as covariate was used. All hypotheses were tested at a 5% level of significance.) · Mean difference (final values): 1.20 · 95% CI 0.82 to 1.59No adjustments were made for multiple comparisons.
SecondaryChange From Baseline in Growth Velocity SDS at Month 24.

The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · SDS
Change From Baseline in Growth Velocity SDS at Month 24.
SDSGenotropin®Control
Change From Baseline in Growth Velocity SDS at Month 24.0.74 ± 0.57-0.03 ± 0.57
Statistical analysis
  • Genotropin® vs Control · ANCOVA · p = 0.348 (ANCOVA model, fitting treatment as a factor, and the baseline parameter value as covariate was used. All hypotheses were tested at a 5% level of significance.) · Mean difference (final values): 0.77 · 95% CI -0.87 to 2.42No adjustments were made for multiple comparisons.
SecondaryChange From Baseline in Height SDS at Month 12.

Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · SDS
Change From Baseline in Height SDS at Month 12.
SDSGenotropin®Control
Change From Baseline in Height SDS at Month 12.1.03 ± 0.120.14 ± 0.12
Statistical analysis
  • Genotropin® vs Control · ANCOVA · p = <0.001 (ANCOVA model, fitting treatment as a factor, and the baseline parameter value as covariate was used. All hypotheses were tested at a 5% level of significance.) · Mean difference (final values): 0.89 · 95% CI 0.55 to 1.23No adjustments were made for multiple comparisons.
SecondaryChange From Baseline in Growth Velocity SDS at Month 12.

The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · SDS
Change From Baseline in Growth Velocity SDS at Month 12.
SDSGenotropin®Control
Change From Baseline in Growth Velocity SDS at Month 12.1.65 ± 0.56-1.59 ± 0.56
Statistical analysis
  • Genotropin® vs Control · ANCOVA · p = <0.001 (ANCOVA model, fitting treatment as a factor, and the baseline parameter value as covariate was used. All hypotheses were tested at a 5% level of significance.) · Mean difference (final values): 3.24 · 95% CI 1.63 to 4.85No adjustments were made for multiple comparisons.
SecondaryChange From Baseline in Mental Development Using the Mental Development Index (MDI) of Bayley Scale at Month 12.

The Bayley Scale of Infant Development (BSID-II) measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the mental raw score which was used to calculate the MDI score. Possible MDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Mental Development Using the Mental Development Index (MDI) of Bayley Scale at Month 12.
Units on a scaleGenotropin®Control
Change From Baseline in Mental Development Using the Mental Development Index (MDI) of Bayley Scale at Month 12.10.97 ± 5.348.55 ± 4.74
Statistical analysis
  • Genotropin® vs Control · ANCOVA · p = 0.738 (ANCOVA model, fitting treatment as a factor, and the baseline parameter value, age, and gender as covariates were used. All hypotheses were tested at a 5% level of significance.) · Mean difference (final values): 2.43 · 95% CI -12.27 to 17.12No adjustments were made for multiple comparisons.
SecondaryChange From Baseline in Psychomotor Development Using the Psychomotor Development Index (PDI) of Bayley Scale at Month 12.

BSID-II measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the psychomotor raw score which was used to calculate the PDI score. Possible PDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Psychomotor Development Using the Psychomotor Development Index (PDI) of Bayley Scale at Month 12.
Units on a scaleGenotropin®Control
Change From Baseline in Psychomotor Development Using the Psychomotor Development Index (PDI) of Bayley Scale at Month 12.4.04 ± 3.048.55 ± 2.84
Statistical analysis
  • Genotropin® vs Control · ANCOVA · p = 0.301 (ANCOVA model, fitting treatment as a factor, and the baseline parameter value, age, and gender as covariates were used. All hypotheses were tested at a 5% level of significance.) · Mean difference (final values): -4.51 · 95% CI -13.27 to 4.26No adjustments were made for multiple comparisons.
SecondaryHead Circumference SDS at Months 3, 6, 12, 18 and 24.

Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/ Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.

Time frame:
Months 3, 6, 12, 18 and 24
Reported as:
Mean · SDS
Head Circumference SDS at Months 3, 6, 12, 18 and 24.
SDSGenotropin®Control
Month 3 (n = 21, 19)-0.93 ± 1.217-1.37 ± 1.122
Month 6 (n = 21, 19)-1.20 ± 1.310-1.72 ± 1.077
Month 12 (n = 20, 18)-0.87 ± 1.330-1.84 ± 1.158
Month 18 (n = 20, 19)-0.56 ± 1.890-1.76 ± 1.153
Month 24 (n = 20, 20)-0.75 ± 1.384-1.65 ± 1.227
SecondaryChange From Baseline in Head Circumference SDS at Months 3, 6, 12, 18 and 24.

Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.

Time frame:
Baseline, Months 3, 6, 12, 18 and 24.
Reported as:
Mean · SDS
Change From Baseline in Head Circumference SDS at Months 3, 6, 12, 18 and 24.
SDSGenotropin®Control
Month 3 (n = 21, 19)0.27 ± 0.9770.36 ± 0.693
Month 6 (n = 21, 19)-0.00 ± 0.4230.07 ± 0.495
Month 12 (n = 20, 18)0.26 ± 0.5160.02 ± 0.587
Month 18 (n = 20, 19)0.57 ± 1.0940.04 ± 0.506
Month 24 (n = 20, 20)0.39 ± 0.6380.08 ± 0.602
SecondaryChange From Baseline in Body Weight at Months 3, 6, 12, 18, and 24.

Body weight was measured at all the relevant visits. The change from Baseline in body weight was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.

Time frame:
Baseline, Months 3, 6, 12, 18, and 24
Reported as:
Mean · Kg
Change From Baseline in Body Weight at Months 3, 6, 12, 18, and 24.
KgGenotropin®Control
Month 3 (n = 21, 19)0.57 ± 0.1540.53 ± 0.406
Month 6 (n = 21, 20)1.08 ± 0.2691.01 ± 0.659
Month 12 (n = 20, 19)2.34 ± 0.3891.66 ± 0.397
Month 18 (n = 20, 19)3.48 ± 0.6692.41 ± 0.709
Month 24 (n = 20, 20)4.79 ± 0.8143.19 ± 0.601
SecondaryChange From Baseline in Body Mass Index (BMI) at Months 3, 6, 12, 18, and 24.

Body mass index was calculated for all visits by means of the following formula: BMI (kg/m2) = Weight (kg)/(Height\[m\])2. The change from Baseline BMI was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.

Time frame:
Baseline, Months 3, 6, 12, 18, and 24
Reported as:
Mean · Kg/m2
Change From Baseline in Body Mass Index (BMI) at Months 3, 6, 12, 18, and 24.
Kg/m2Genotropin®Control
Month 3 (n = 21, 19)-0.28 ± 0.419-0.05 ± 0.811
Month 6 (n = 21, 20)-0.57 ± 0.5370.08 ± 1.013
Month 12 (n = 20, 19)-0.62 ± 0.650-0.29 ± 0.683
Month 18 (n = 20, 19)-0.78 ± 0.930-0.25 ± 0.806
Month 24 (n = 20, 20)-0.58 ± 0.823-0.55 ± 0.776

Adverse events

Collected over Up to the participant's age of 49 to 55 months (Follow-up visit). Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Genotropin®—6/21 (28.6%)21/21 (100%)
Control—2/22 (9.1%)18/22 (81.8%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventGenotropin®Control
Conductive deafnessEar and labyrinth disorders2/210/22
BronchopneumoniaInfections and infestations1/210/22
GastroenteritisInfections and infestations1/211/22
HordeolumInfections and infestations1/210/22
Viral infectionInfections and infestations1/210/22
ConcussionInjury, poisoning and procedural complications1/210/22
DehydrationMetabolism and nutrition disorders1/210/22
Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders1/210/22
AsthmaRespiratory, thoracic and mediastinal disorders1/210/22
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders1/210/22
Most frequent other events
Showing 10 of 62
Most frequent other events
EventGenotropin®Control
PyrexiaGeneral disorders9/214/22
NasopharyngitisInfections and infestations8/216/22
Upper respiratory tract infectionInfections and infestations8/211/22
BronchitisInfections and infestations6/216/22
DiarrhoeaGastrointestinal disorders4/210/22
VomitingGastrointestinal disorders4/214/22
LaryngitisInfections and infestations4/210/22
VaricellaInfections and infestations4/211/22
ConjunctivitisEye disorders3/212/22
Ear infectionInfections and infestations3/211/22

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Genotropin®ControlTotal
Mean24.91 ± 3.26224.44 ± 3.32424.67 ± 3.263
Sex: Female, Male
Sex: Female, Male(Participants)Genotropin®ControlTotal
Female131124
Male81119
08

Study locations

17 sites
  • Universitair Ziekenhuis Brussel/Pediatrie
    Brussel, 1090, Belgium
  • Universitair Ziekenhuis Antwerpen / Pediatrie
    Edegem, 2650, Belgium
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czech Republic
  • Fakultni nemocnice Ostrava, Detska klinika
    Ostrava-Poruba, 708 52, Czech Republic
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czech Republic
  • CHU Toulouse, Hôpital des Enfants, Service Endocrinologie
    Toulouse Cedex 9, 31059, France
  • Universitaetsklinikum Erlangen, Kinder- und Jugendklinik
    Erlangen, 91054, Germany
  • Centro di Endocrinologia Pediatrica, Dipartimento di Pediatria
    Catania, 95125, Italy
  • Policlinico Universitario, Istituto di Clinica Pediatrica
    Messina, 98100, Italy
  • Dipartimento Materno Infantile, UO di Pediatria e Neonatologia
    Milano, 20132, Italy
  • Dipartimento di Medicina Pediatrica, UO di Endocrinologia e Diabetologia
    Roma, 00165, Italy
  • Sophia Children's Hospital
    Rotterdam, 3015 GJ, Netherlands
  • Consorci Hospitalari Parc Tauli
    Sabadell, Barcelona 08208, Spain
  • Hospital Virgen Del Camino
    Pamplona, Navarra 31008, Spain
  • Hospital Miguel Servet
    Zaragoza, 50009, Spain
  • Drottning Silvias Barn och Ungdomssjukhus
    Göteborg, Sweden
  • Inselspital
    CH-3010 Bern, Switzerland
09

References and documents

Publications

  • De Schepper J, Vanderfaeillie J, Mullis PE, Rooman R, Robertson A, Dilleen M, Gomez R, Wollmann HA. A 2-year multicentre, open-label, randomized, controlled study of growth hormone (Genotropin(R)) treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) Study. Clin Endocrinol (Oxf). 2016 Mar;84(3):353-60. doi: 10.1111/cen.12968. Epub 2015 Nov 25. PubMed 26501737 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2008
First posted
Mar 3, 2008
Start
Feb 2008
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Sep 18, 2014
Last update
Nov 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00627523
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 3, 2008
Start date
Feb 2008
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Sep 18, 2014
Last update
Nov 4, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion